The effectiveness of secretin in the management of autism

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 2, 2004, Pages 379-387

  Kern, Janet K ^a   Espinoza, Elvira ^a   Trivedi, Madhukar H ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Autism; Efficacy; Measures; Secretin; Subtypes; Trials

Indexed keywords

CENTRAL STIMULANT AGENT; PLACEBO; RG 1068; SECRETIN; SECRETIN DERIVATIVE; UNCLASSIFIED DRUG;

AUTISM; BEHAVIOR THERAPY; CHILD; CLINICAL TRIAL; DRUG EFFICACY; FLUSHING; HEMATOLOGIC DISEASE; HUMAN; INTERPERSONAL COMMUNICATION; NEUROLOGIC DISEASE; NONHUMAN; OUTCOMES RESEARCH; PARENT; PSYCHOLOGIC ASSESSMENT; RATING SCALE; REVIEW; SIDE EFFECT; SOCIAL INTERACTION; SYMPTOMATOLOGY; TACHYCARDIA;

ANIMALS; AUTISTIC DISORDER; HUMANS; SECRETIN; TREATMENT OUTCOME;

EID: 1242296776     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.2.379     Document Type: Review

References (53)

1. FILIPEK PA, ACCARDO PJ, BARANEK GT et al.: The screening and diagnosis of autistic spectrum disorders. J. Autism Dev. Disord. (1999) 29(6):437-482.
2. AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and statistical manual of mental disorders (4th edn). Author, Washington, DC (1994).
3. LORD C: Diagnostic instruments in autism spectrum disorders. In: Handbook of Autism and Pervasive Developmental Disorders (2nd edn). Cohen DJ, Volkmar FR (Eds), John Wiley & Sons, Inc., New York (1997):460-508.
4. WING L: Syndromes of autism and atypical development. In: Handbook of Autism and Pervasive Developmental Disorders (2nd edn). Cohen DJ, Volkmar FR (Eds), John Wiley & Sons, Inc., New York (1997 ):148-170.
5. GILLBERG C: Neurodevelopmental processes and psychological functioning in autism. Dev. Psychopathol. (1999) 11(3):567-587.
6. KERN JK: The possible role of the cerebellum in autism/PDD: disruption in a multisensory feedback loop. Med. Hypotheses (2002) 59(3):255-260.
7. COURCHESNE E: New evidence of cerebellar and brain stem hypoplasia in autistic infants, children, and adolescents: the MR imaging study by Hashimoto and colleagues. J. Autism Dev. Disord. (1995) 25(1):19-22.
8. WARREN RP, YONK J, BURGER RW, ODELL D, WARREN WL: DR-positive T cells in autism: association with decreased plasma levels of the complement C4B protein. Neuropsychobiology (1995) 31(2):53-57.
9. HORVATH K, PAPADIMITRIOU JC, RABSZTYN A, DRACHENBERG C, TILDON JT: Gastrointestinal abnormalities In children with autistic disorder. J. Pediatrics (1999) 135(5):559-563.
10. FURLANO RI, ANTHONY A, DAY R et al.: Colonic CD8 and γδT-cell infiltration with epithelial damage in children with autism. J. Pediatrics (2001)138(3):366-372.
11. WARING RH, KLOVRZA LV: Sulphur metabolism in autism. J. Nutr. Environ. Med. (2000) 10:25-32.
12. BOTTINI N, DE KUCA D, SACCUCCI P et al.: Autism: evidence of association with adenosine deaminase. Neurogenetics (2001) 3(2):111-113.
13. KERN JK, MILLER VS, CAULLER LJ, KENDALL R, MEHTA J, DODD M: The effectiveness of N, N-dimethylglycine in autism/PDD. J. Child. Neurol. (2001) 16(3):169-173.
14. KERN JK, MILLER VS, EVANS PA, TRIVEDI MH: Efficacy of porcine secretin in children with autism and pervasive developmental disorder. J. Autism Dev. Disord. (2002) 32(3):153-160.
15. RUTTER M, BAILEY A, SIMONOFF E, PICKLES A: Genetic influences and autism: In: Handbook of Autism and Pervasive Developmental Disorders (2nd edn). Cohen DJ, Volkmar FR (Eds), John Wiley & Sons, Inc., New York (1997):370-387.
16. GILLBERG C: Chromosomal disorders and autism. J. Autism Dev. Disord. (1998) 28(5):415-425.
17. CHESS S: Follow-up report on autism in congenital rubella. J. Autism Dev. Disord. (1977) 7:68-81.
18. BRYSON SE, CLARK BS, SMITH IM: First report of a Canadian epidemiological study of autistic syndromes. J. Child Psychol. Psychiatry (1988) 29:433-446.
19. SUGIYAMA T, ABE T: The prevalence of autism in Nagoya, Japan: a total population study. J. Autism Dev. Disord. (1989) 19:87-96.
20. WING L, GOULD J: Severe impairments of social interaction and associated abnormalities in children: epidemiological and classification. J. Autism Dev. Disord. (1979) 9:11-29.
21. BAIRD G, CHARMAN T, BARON-COHEN S et al.: Screening a large population of 18 months olds with the CHAT. Paper presented at the Proceedings of the Society for Research on Child Development, Albuquerque, USA (1999).
22. AMAN M, SINGH N: Aberrant Behavior Checklist. Slosson Educational Publications, Inc., New York (1986).
23. SCHOPLER E, REICHLER RJ, RENNER BR: The Childhood Autism Rating Scale. Western Psychological Services, 12031 Wilshire Boulevard, Los Angeles, CA 90025-1251 (1994).
24. LORD C, RUTTER M, DILAVORE PC, RISI S: Autism Diagnostic Observation Schedule. Western Psychological Services, 12031 Wilshire Blvd, Los Angeles, CA 90025-1251 (1999).
25. LEITER R: International Performance Scale. IL, Stoeling, Chicago (1948).
26. ZIMMERMAN I, STEINER V, POND R: Preschool Language Scale-3. The Psychological Corporation, San Antonio, TX (1992).
27. LIGHTDALE JR, HAYER C, DUER A et al.: Effects of intravenous secretin on language and behavior of children with autism and gastrointestinal symptoms: a single-blinded, open-label pilot study. Pediatrics (2001) 108(5):E90.
28. FENSON L, DALE PS, REZNICK JS et al.: MacArthur Communicative Development Inventories. Singular Publishing Group, Inc., London (1996).
29. KRUG D, ARICK J, ALMOND P: Autism Behavior Checklist. Austin, TX: PRO-ED. (1980).
30. SPARROWS, BALLA D, CICCHETTI D. Vineland Adaptive Behavior Scales. Circle Pines, MN, American Guidance Service (1994).
31. YAMAGATA T, ARADHYA S, MORI M, INOUE K, MOMOI MY, NELSON DL: The human secretin gene: fine structure in 11p15.5 and sequence variation in patients with autism. Genomics (2002) 80(2):185-194.
32. MITZNEGG P, BLOOM SR, DOMSCHKE W et al.: Effect of secretin in plasma motilin in man. Gut (1977) 18:468-471.
33. HORVATH K, STEFANATOS G, SOKOLSKI KN, WACHTEL R, NABORS L, TILDON J: Improved social and language skills after secretin administration in patients with autistic spectrum disorders. J. Assoc. Acad. Minor. Physicians (1998) 9:9-15.
34. BANKS WA, GOULET M, RUSCHE JR, NIEHOFF ML, BOISMENU R: Differential transport of a secretin analog across the blood-brain and blood-cerebrospinal flud barriers of the mouse. J. Pharmacol. Exp. Ther. (2002) 302(3):1062-1069.
35. GOULET M, SHIROMANI PJ, WARE CM, STRONG RA, BOISMENU R, RUSCHE JR: A secretin I.V. infusion activates gene expression in the central amygala of rats. Neuroscience (2003) 118:881-888.
36. YUNG WH, LEUNG PS, NG SSM et al.: Secretin facilitates GABA transmission in the cerebellum. J. Neurosci. (2001) 21(18):7063-7068.
37. COURCHESNE E: Brainstem, cerebellar and limbic neuroanatomical abnormalities in autism. Curr. Opin. Neurobiol. (1997) 7:269-278.
38. RIVA D, GIORGI C: The cerebellum contributes to higher functions during development: evidence from a series of children surgically treated for posterior fossa tumors. Brain (2000) 123:1051-1061.
39. KOVES K, KAUSZ M, RESER D, HORVATH K: What may be the anatomical basis that secretin can improve the mental functions in autism? Regul. Pept. (2002) 15;109(1-3):167-72.
40. 125I-secretin receptor binding sites in rat brain. Biochem. Biophys. Res. Commun. (2002) 292:133-137.
41. SANDLER AD, SUTTON KA, DEWEESE J, GIRARDI MA, SHEPARD V, BODFISH JW: Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. N. Engl. J. Med. (1999) 341(24):1801-1806.
42. CHEZ MG, BUCHANAN CP, BAGAN BT et al.: Secretin and autism: a two part clinical investigation. J. Autism Dev. Disord. (2000) 30:87-94.
43. DUNN-GEIER J, HO HH, AUESPERG E et al.: Effect of secretin on childten with autism: a randomized controlled trial. Dev. Med. Child Neurol. (2000) 42:796-802.
44. CONIGLIO SJ, LEWIS JD, LANG C et al.: A randomized, double-blind, placebo-controlled trial of single-dose intravenous secretin treatment for children with autism. J. Pediatr. (2001) 138:649-655.
45. LAMSON DW, PLAZA SM: Transdermal secretin for autism- a case report. Altern. Med. Rev. (2001) 6:311-313.
46. ROBERTS W, WEAVER L, BRIAN J et al.: Repeated doses of porcine secretin in the treatment of autism: a randomized, placebo-controlled trial. Pediatrics (2001) 107(5):E71.
47. CORBETT B, KHAN K, CZAPANSKY-BEILMAN D et al.: A double-blind, placebo-controlled crossover study investigating the effect of porcine secretin in children with autism. Clin. Pediatr. (2001) 40:327-331.
48. CAREY T, RATLIFF-SCHAUB K, FUNK J, WEINLE C, MYERS M, JENKS J: Double-blind placebo-controlled trial of secretin: effects on aberrant behavior in children with autism. J. Autism Dev. Disord. (2002) 32(3):161-167.
49. UNIS AS, MUNSON JA, ROGERS SJ et al.: A randomized, double-blind, placebo-controlled trial of porcine versus synthetic secretin for reducing symptoms of autism. J. Am. Acad. Child Adolesc. Psychiatry (2002) 44(11):1315-1321.
50. SPONHEIM E, OFTEDAL G, HELVESCHOU SB: Multiple doses of secretin in the treatment of autism: a controlled study. Acta. Paediatr. (2002) 91:540-545.
51. MOLLOY CA, MANNING-COURTNEY P, SWAYNE S et al.: Lack of benefit of intravenous synthetic human secretin in the treatment of autism. J. Autism Dev. Disord. (2002) 32(6):545-551.
52. REPLIGEN CORPORATION: SecreFlo™ Clinical Trials. Repligen Corporation, Building 1, Suite 100, 41 Seyon Street, Waltham, MA 02453.
53. LEVY SE, SOUDERS MC, WRAY J et al.: Children with autistic spectrum disorders. 1: comparison of placebo and single dose of human synthetic secretin. Arch. Dis. Child (2003) 88:731-736.